DC
Therapeutic Areas
Avata Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AVAT-021 | Adult Focal Epilepsy | Phase 2 |
| AVAT-021 (Pediatric) | Pediatric Focal Epilepsy | Preclinical/Phase 1 |
| AVAT-022 | Pediatric Focal Epilepsy | Discovery/Preclinical |
| AVAT-031 | Schizophrenia | Discovery |
| AVAT-041 | Opioid Sparing/Addiction | Discovery |
Leadership Team at Avata Biosciences
JB
Julian Bryson
Executive Chairman & Cofounder
RH
Rupert Haynes
Chief Executive Officer & Cofounder
DA
Dr. Andrew Saich
Chief Medical Officer & Cofounder
DV
Dr. Venkat Goskonda
Chief Scientific Officer
GP
Grace Powell
Head of Regulatory Affairs
JG
Jim Gillespie
Program Director
DE
Dr. Emma Cheetham
Patent Portfolio Director